Open Your FREE Demat Account Now!

Ipca Laboratories Ltd. Share Price

NSE
BSE

NSE : IPCALAB

BSE : 524494

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Low

₹1,834.00

High

₹1,855.00

Price Summary

Previous Close ₹1,851.80
Day's Range ₹1,834.00 - ₹1,855.00
Open ₹1,834.40
52 Week Range ₹1,361.70 - ₹2,038.00
Volume 24,666
Market Cap ₹0.05
Previous Close ₹1,853.00
Day's Range ₹1,834.05 - ₹1,855.00
Open ₹1,840.00
52 Week Range ₹1,363.00 - ₹2,039.30
Volume 1,416
Market Cap ₹0.05

Stocks Summary

Trade Value ( ₹ in Lacs) 456.76
Market Cap (₹ in Mn) 0.05
Dividend Yield(%) 0.33
Price/Earning (TTM) 33.17
TTM EPS (₹) 55.28
P/E Ratio 35.64
Book Value(₹) 5.36
PAT Margin (%) 12.35
Face Value (₹) 1.00
ROCE(%) 19.41
Trade Value ( ₹ in Lacs) 26.24
Market Cap (₹ in Mn) 0.05
Dividend Yield(%) 0.33
Price/Earning (TTM) 33.17
TTM EPS (₹) 55.28
P/E Ratio 35.64
Book Value(₹) 5.36
PAT Margin (%) 12.35
Face Value (₹) 1.00
ROCE(%) 19.41

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 19303.2 89395.9
Expenses N/A N/A
PBT 4083.1 11288.5
Operating profit 0.0 0.0
Net profit 3047.4 7852.4

Shareholding Pattern

Promoters (% Holding)

44.72%

Mutual funds (% Holding)

31.07%

Non-Institution (% Holding)

7.15%

FI/Banks/Insurance (% Holding)

4.76%

Government (% Holding)

0.00%

FII

11.52%

About Ipca Laboratories Ltd.

Founded 1949
Managing Director Pranay Godha
NSE Symbol IPCALAB

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,48,687.64 1,870.60 1,583.70 - 1,583.70
Divi's Laboratories Ltd. 2,95,080.27 11,198.15 5,647.50 - 5,647.50
Torrent Pharmaceuticals Ltd. 1,77,677.43 4,674.90 3,672.30 - 3,672.30
Lenskart Solutions Ltd. 1,28,551.39 737.05 0.00 - 0.00
Laurus Labs Ltd. 1,26,433.06 2,335.00 917.95 - 917.95
Apollo Hospitals Enterprise Ltd. 1,25,112.06 8,766.00 6,696.50 - 6,696.50
Zydus Lifesciences Ltd. 1,19,969.79 1,201.00 835.50 - 835.50
Dr. Reddy's Laboratories Ltd. 1,15,852.16 1,380.30 1,101.00 - 1,101.00
Cipla Ltd. 1,11,730.92 1,390.50 1,165.70 - 1,165.70
Mankind Pharma Ltd. 1,07,612.70 2,629.80 1,909.70 - 1,909.70
no-content No Records Found

Latest News

Oct
22
2026
EQUITY Posted on Oct 22nd 2026

Ipca Laboratories informs about board meeting

Ipca Laboratories has informed that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 consider and approve Standalone and Consolidated Unaudited Financial Results for the second quarter and half year ended 30.09.2026,
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
18
2026
COMPANY Posted on Nov 18th 2026

KRM Ayurveda - Quaterly Results

The sales surged to Rs. 347.14 millions, up 46.53% for the September 2026 quarter as against Rs. 236.91 millions during the corresponding quarter previous year.Profit after tax for the quarter ended September 2026 reported a huge growth of 97.31% to Rs. 82.28  millions from Rs. 41.70 millions.OP of the company witnessed a marginal growth to 113.36 millions from 68.85 millions in the same quarter last year.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202603 202503 % Var
Sales 347.14 236.91 46.53 670.37 483.57 38.63 1016.91 765.53 32.84
Other Income 6.43 1.47 337.41 11.86 2.97 299.33 6.23 3.97 56.93
PBIDT 113.36 68.85 64.65 238.97 132.49 80.37 311.20 191.41 62.58
Interest 0.82 10.21 -91.97 1.44 17.11 -91.58 32.51 28.99 12.14
PBDT 112.54 58.64 91.92 237.53 115.38 105.87 278.69 162.42 71.59
Depreciation 3.82 2.82 35.46 6.46 5.35 20.75 11.44 10.44 9.58
PBT 108.72 55.82 94.77 231.07 110.03 110.01 267.25 151.98 75.85
TAX 26.44 14.12 87.25 57.94 27.81 108.34 66.06 39.84 65.81
Deferred Tax -0.98 0.08 -1325.00 -0.85 0.14 -707.14 -2.68 0.30 -993.33
PAT 82.28 41.70 97.31 173.13 82.22 110.57 201.19 112.14 79.41
Equity 212.61 155.21 36.98 212.61 155.21 36.98 212.61 1.50 14074.00
PBIDTM(%) 32.66 29.06 12.37 35.65 27.40 30.11 30.60 25.00 22.39
Read More
Nov
17
2026
EQUITY Posted on Nov 17th 2026

GlaxoSmithKline Pharmaceuticals informs about postal ballot notice

GlaxoSmithKline Pharmaceuticals has informed that it enclosed a copy of Postal Ballot Notice pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, which is being sent to the Members of the Company seeking their approval for Related Party Transactions with GSK Biological S.A. (Belgium). In compliance with the Circulars of the Ministry of Corporate Affairs, the said Notice is being sent electronically only to those Members, whose names appear in the Register of Members/ List of Beneficial Owners as received from National Securities Depository (‘NSDL’)/ Central Depository Services (India) (‘CDSL’) and who have registered their e-mail addresses in respect of electronic holdings with NSDL/CDSL through the concerned Depository Participants and in respect of physical holdings with the Company’s Registrar and Share Transfer Agent (RTA) - KFin Technologies as on Friday, 13th November 2026 (cut-off date). The e-voting shall commence on Wednesday, 18th November, 2026 and ends at 05.00 PM (IST) on Thursday, 17th December, 2026. The copy of the said Notice is also available on the website of the Company at https://india-pharma.gsk.com/en-in/investors/shareholder-information/postal-ballot/ and on the website of Kfintech https://evoting.kfintech.com/.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
17
2026
EQUITY Posted on Nov 17th 2026

AstraZeneca Pharma India informs about letter of intent

AstraZeneca Pharma India has informed that the Company has signed a Letter of Intent (‘LOI’) with Strand Life Sciences (‘Strand’), a genomics research and diagnostics company and a subsidiary of Reliance Industries, to explore opportunities to collaborate in healthcare in India. The Company and Strand are not related parties, and the execution of the LOI does not constitute a related party transaction. Communication in relation to the above is disseminated through the LinkedIn handle of the Company and is accessible at AstraZeneca India. The above information is also being made available on the website of the Company at www.astrazeneca.com/india.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
17
2026
EQUITY Posted on Nov 17th 2026

Star Imaging And Path Lab informs about investor presentation

Star Imaging And Path Lab has informed that it enclosed a copy of Investor Presentation based on the Unaudited (Standalone and Consolidated) Financial Results of the Company for the half year ended September 30, 2026, along with the Limited Review Report thereon. The Investor Presentation are also being made available on the Company’s website at www.Starimaging.in
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Ipca Laboratories Ltd. ?

The current share price of Ipca Laboratories Ltd. is ₹1,851.80 as of 2026-11-18.

The market capitalisation of Ipca Laboratories Ltd. is ₹46,510.33 as of 2026-11-17.

The 1-year return of Ipca Laboratories Ltd. is 387.00% as of 2026-11-18.

The P/E ratio of Ipca Laboratories Ltd. is 35.64 as of 2026-11-18.

The 52-week high and low of Ipca Laboratories Ltd. are ₹2,038.00 and ₹1,361.70, respectively, as of 2026-11-18.

The dividend yield of Ipca Laboratories Ltd. is 0.3273% as of2026-11-17.

You can buy Ipca Laboratories Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Ipca Laboratories Ltd. is Pranay Godha.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

People Also Ask

Which healthcare formulations and products are manufactured by Ipca Laboratories Ltd.?

Ipca Laboratories Ltd. manufactures a vast array of active pharmaceutical ingredients (APIs) and finished drug formulations. The company holds dominant global market shares in producing anti-malarial, rheumatology, and cardiovascular medications, serving both domestic retail and heavy international export markets.

Ipca Laboratories Ltd. works with global entities by exporting heavily vertically integrated APIs and formulations to over 100 countries. It partners with domestic hospitals and clinics through a massive medical representative network that ensures widespread availability of its specialised generic drugs.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore